KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Common Equity: 2011-2025

Historic Common Equity for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $1.3 billion.

  • Sarepta Therapeutics' Common Equity rose 8.11% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 8.11%. This contributed to the annual value of $1.5 billion for FY2024, which is 77.78% up from last year.
  • Sarepta Therapeutics' Common Equity amounted to $1.3 billion in Q3 2025, which was down 2.75% from $1.4 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Common Equity's 5-year high stood at $1.5 billion during Q4 2024, with a 5-year trough of $384.9 million in Q4 2022.
  • Moreover, its 3-year median value for Common Equity was $1.1 billion (2024), whereas its average is $1.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 58.52% in 2022, then surged by 123.23% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Common Equity (Quarterly) stood at $928.0 million in 2021, then tumbled by 58.52% to $384.9 million in 2022, then skyrocketed by 123.23% to $859.3 million in 2023, then surged by 77.78% to $1.5 billion in 2024, then climbed by 8.11% to $1.3 billion in 2025.
  • Its Common Equity stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.1 billion for Q1 2025.